The company, which has seen its stock price climb nearly fivefold over the past twelve months, is positioning the drug as a critical intervention for a disease notoriously resistant to existing treatments. Because pancreatic cancer is frequently detected only in its terminal stages, the medical community remains focused on high-mortality outcomes that current protocols struggle to mitigate.

Beyond the U.S. regulatory process, the European Medicines Agency has initiated a phased review of the therapy through its Committee for Medicinal Products for Human Use. This staggered approach allows regulators to evaluate clinical data as it emerges, potentially accelerating the path to a formal marketing authorization application in European markets.